A Phase 4 Comparative Trial of Benzathine Penicillin G 2.4 Million Units Administered as a Single Dose versus Three Successive Weekly Doses for Treatment of Early Syphilis in Subjects with or without HIV Infection
T
Teresa Batteiger, MD
Primary Investigator
Administratively Closed
18 years - 100 years
All
Phase
4
20 participants needed
1 Location
Brief description of study
The purposes of this study are to compare the effect of 1 dose of Benzathine Penicillin G (BPG) to 3 weekly doses of BPG in all subjects; and to determine whether the effects of 1 dose of BPG or 3 weekly doses of BPG are different in HIV-infected and HIV-uninfected subjects.
Detailed description of study
Adults 18 years of age and older are needed for a study assessing syphilis treatment. This study is being conducted by Dr. Teresa Batteiger at Indiana University School of Medicine. The study takes place in the Bell Flower Clinic of the Fifth Third Office Building, next to Eskenazi Hospital.
This study will compare the effect of one dose to three doses (one dose a week for three weeks in a row) of medication normally given for treatment of Syphilis in individuals with or without HIV infection. Volunteers must have early syphilis but have not been treated yet. You will be paid for your participation. The total duration of participation is 12 months, with 8 visits over that time. Risks will be disclosed prior to study enrollment.
For information or to see if you qualify, call Lora at 317-274-8453.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: syphilis,HIV,1804212716
-
Age: 18 years - 100 years
-
Gender: All
Adults 18 years of age and older
Volunteers must have early syphilis but have not been treated yet.
Additional Information:
Updated on
07 Jan 2025.
Study ID: 1804212716
